Advanced pancreatic cancer is diagnosed by gastric juice cytology in < 50% of cases. That constitutes a major limitation of endoscopic retrograde cholangiopancreatography (ERCP). (a) Was SPACE informative in this patient due to serial testing alone or was it so because of the large size of PCIS, measuring close to stage-1 tumor? (b) Can SPACE be routinely advised to establish or exclude the diagnosis of PCIS in patients with abnormal pancreatic morphology? However, with consensus on frequency and duration of sampling, SPACE appears to have potential for global acceptance as a preferred technique. It may facilitate juice analysis for cytokines, molecules of malignancy and tumor markers. Moreover, special contrasts, enhancers and dyes may be injected through endoscopic naso-pancreatic drainage catheter for PCIS imaging.